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Abstract
Background: Successful tuberculosis (TB) treatment is essential to effective TB control. TB-HIV coinfection, social
determinants and access to services influenced by rural residence can affect treatment outcome. We examined the
separate and joint effects of rural residence and HIV infection on poor treatment outcome among patients enrolled
in a large TB treatment centre in Kano, Nigeria.
Methods: We retrospectively analysed a cohort of patients with TB enrolled in a large urban TB clinic in northern
Nigeria, from January 2010 to December 2014. Poor treatment outcome was defined as death, default or treatment
failure. We used Poisson regression to model rates and determine the relative risks (and 95% confidence intervals,
CI) of poor treatment outcomes.
Results: Among 1381 patients included in the analysis, 28.4% were rural residents; 39.8% were HIV-positive; and
46.1% had a poor treatment outcome. Approximately 65 and 38% of rural and urban residents, respectively, had a
poor treatment outcome. Rural residents had 2.74 times (95% CI: 2.27–3.29) the risk of having a poor treatment
outcome compared to urban residents. HIV-positive patients had 1.4 times (95% CI: 1.16–1.69) the risk of poor
treatment outcome compared to HIV-negative patients. The proportion of poor treatment outcome attributable to
rural residence (population attributable fraction, PAF) was 25.6%. The PAF for HIV infection was 11.9%. The effect of
rural residence on poor treatment outcome among HIV-negative patients (aRR:4.07; 95%CI:3.15–5.25) was more than
twice that among HIV-positive patients (aRR:1.99; 95%CI:1.49–2.64).
Conclusion: Rural residents attending a large Nigerian TB clinic are at increased risk of having poor treatment
outcomes, and this risk is amplified among those that are HIV-negative. Our findings indicate that rural coverage
of HIV services may be better than TB services. These findings highlight the importance of expanding coverage
of TB services to ensure prompt diagnosis and commencement of treatment, especially among rural-dwellers in
resource-limited settings.
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Background
Effective tuberculosis (TB) control is largely dependent
on successful treatment. Between 2000 and 2014, 43 million
deaths were prevented through effective TB treatment and
global TB deaths have declined by almost half from 1990.
[1] Despite this progress, each year over 1 million deaths
from TB occur and about 3.6 million people with TB are
still missed by health systems annually and therefore fail to
receive appropriate care. [2] The importance of identifying
sub-groups with high risk of TB and its consequences has
been emphasised. [3, 4] The End TB Strategy recognises
the need to address underlying social determinants
(poverty, food insecurity, poor living and working condi-
tions) and consequences (catastrophic economic costs,
stigmatisation, social isolation, loss of job and divorce) of
TB to effectively control the disease. [5–7] HIV infection,
one of the major drivers of TB burden in sub-Saharan
(SSA) also complicates diagnosis and treatment of TB,
and is associated with poorer treatment outcomes, such as
treatment failure and death. Early diagnosis and prompt
initiation of treatment with anti-tuberculous medications
reduce infectiousness, transmission, deaths and other poor
outcomes, including treatment failure and drug resistance.
Nigeria is a high burden country with regards absolute
number of TB cases, TB-HIV co-infection and multi-
drug resistance. [8] An estimated 586,000 new TB cases
(322/100,000 population) and 240,000 TB-related deaths
occur in Nigeria yearly. [9] TB control in Nigeria is
managed by the TB and Leprosy Control Programmes
operating at the three levels of healthcare. [10] TB in
Nigeria is largely externally funded through the Global
Fund to fight AIDS, TB and Malaria (GFATM), and the
United States Agency for International Development
(USAID) through Challenge TB; and to a lesser extent
domestically, with persistent funding gaps especially at
lower government levels. [11–13] TB treatment and
microscopy services are provided free across treatment
centres and microscopy sites in the country, [14] with
lower coverage in the northern states. [11] TB services
are also disproportionately distributed in favour of
urban areas, [14] potentially leaving a larger proportion
of people from rural areas with poor access to TB care.
Geographic barriers related to rural living influence ac-
cess to TB care and clinical outcomes. [3] Additionally,
individual risk factors of rural residents such as low
educational attainment and income can influence care-
seeking behaviours, resulting in treatment delays and
poor treatment adherence. [15] Poor access to health care
could also lead patients to seek less credible alternative
care. [16] Though urban residence is a recognised risk
factor for TB, especially in rapidly urbanising communities
due to poor living conditions, [3] the gap in TB services
coverage between the northern and southern part of the
country, as well as between the rural and urban areas may
have worsened inequalities to treatment access which can
affect the treatment outcome. In addition to providing
specialist services such as diagnosis of extra-pulmonary
and smear-negative TB, several tertiary-level facilities in
the country (which are largely urban-based) also provide
primary care services, such as diagnosis and treatment of
pulmonary TB. This imbalance may also further worsen
rural-urban inequalities in TB care. Establishing the effect
of rural residence in the context of the country with the
4th largest global burden of TB and gross inequalities in
TB services, while adjusting for confounding factors, which
previous studies have not always done, provides important
policy-relevant information.
Due to high TB-burden and disproportionately distrib-
uted TB services in Nigeria, we anticipate that a substantial
number of people in rural areas would need to access care
in large treatment centres within cities. The aim of this
analysis was to describe treatment outcomes and examine
the impact of rural residence and HIV infection on poor
treatment outcomes among TB patients attending a large
urban treatment centre. Our hypothesis is that rural resi-
dents who travel to access care in urban centres have a
higher risk of poor TB treatment outcome, and this risk is
modified by their HIV status. [3]
Methods
Study population
Data from patients age ≥ 15 years and enrolled in Aminu
Kano Teaching Hospital (AKTH) TB clinic for TB
treatment between 2010 and 2014 were included in this
analysis. A total of 43 (2.9%) of 1424 patients that were
transferred to another treatment centre were excluded.
Patients diagnosed with TB received treatment based
on the existing national TB treatment guidelines. [17, 18]
Recommended treatment duration was either 8 months
(up to 2012) or 6 months (from 2013), except for some
cases of extrapulmonary TB - spine and central nervous
system (CNS), where treatment is longer. Treatment
comprised four drugs – Rifampicin (R), Isoniazid (H),
Pyrazinamide (Z) and Ethambutol (E) in the 2-month
intensive phase; and two drugs in the continuation
phase- either Ethambutol and Isoniazid (up to 2012) or
Rifampicin and Isoniazid (from 2013 onwards). Before
drug susceptibility testing became available in the hospital
(2014 onwards), treatment regimen for re-treatment
patients comprised 3-month intensive phase with RHZE
with Streptomycin added in the first 2 months; and
5-month continuation phase with RHE. Patients enrolled
in the clinic included presumed and confirmed TB cases
referred from the same hospital or other hospitals within
and outside Kano. TB/HIV services are co-located and
patients are routinely counselled and screened for HIV, if
their HIV status is unknown.
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Study design
This study was a retrospective cohort design that included
patients who commenced TB treatment from January
2010 to December 2014. Cohort entry was defined as the
date of treatment initiation. Cohort exit was defined as
the first to occur from: treatment completion, death
prior to treatment completion, treatment failure and loss
to follow-up. Follow-up time was ordered by time since
treatment initiation, and tracked as person-months (pm).
Data on independent variables and treatment outcome
were collected from clinic-based records. Information
available from the records included: date of treatment
onset, age, sex, place of residence, mode of diagnosis,
disease site, referral source, HIV status at treatment
onset, history of previous TB treatment and treatment
outcome. Medication intake was observed in the clinic
once a week during the intensive phase, and once a
month during the continuation phase. Daily supervision
of medication intake was performed by an assigned
family member. Data on independent variables were
not updated during follow-up. Site of disease was
grouped as pulmonary (disease affecting lungs only),
extra-pulmonary (disease affecting organs other than
the lung) and both (disease affecting the lungs and any
other organ). The rationale for grouping the disease site
into three and not as done in the National guidelines
(where patients with both pulmonary and extrapulmonary
TB are classified as pulmonary TB), was to allow us to
account for disease severity, as patients with TB involving
2 or more organs tend to have more severe disease. Mode
of diagnosis was grouped as bacteriologically-diagnosed
(sputum-smear or culture confirmed) or clinically diag-
nosed (smear-negative and physician-diagnosed using
clinical features with radiological and/or other laboratory
evidence and a decision to treat with at least 6 months
anti-TB therapy).
The outcome variable was poor treatment outcome,
which was a composite measure comprising death from
any cause including deaths from TB among HIV-positive
persons; treatment failure from lack of conversion or
reversion; and loss to follow-up (LTF) from interruption of
treatment for two consecutive months or more. [19–22]
Outcome was ascertained for 97% of the patients.
The primary exposure variables were: place of residence,
classified as urban (for patients residing in Kano city) and
rural (for patients residing outside Kano city); and
HIV status as at time of treatment onset, classified as
HIV-positive, HIV-negative and unknown HIV status.
Statistical analysis
We summarised categorical variables using frequencies
and proportions. We described the distribution of
explanatory variables in the whole study population and
stratified by treatment outcome status. We also described
the distribution of all potential confounders across strata
of primary exposures (residence and HIV). Univariable
analysis was performed by cross-tabulating independent
variables with treatment outcome, and association assessed
one at a time using chi-squared test.
We examined association between poor treatment
outcome and exposure variables (residence and HIV)
using Poisson regression models. Age, sex and year of
treatment onset were denoted as forced variables and a
priori included in the model. Variables that were associated
with the outcome after adjusting for age, sex and calendar
year at p < 0.2 were included in the multivariable analysis.
A multivariable model was built in a forward stepwise
manner, one variable at a time. Potential confounders were
added sequentially and were retained in the model if they
notably changed the effect estimate (relative risk, RR) by at
least 10%.
We estimated the population attributable fraction (PAF)
of rural residence and HIV status from the final multivariate
model by using the standard formula:
PAF = p’(θ − 1)/ θ.
where p’ denotes the respective proportions of persons with
poor outcome who were rural residents or HIV-positive
and θ represents the relative risks (RR) from the multivari-
able model.
We also examined for interaction between HIV status
and rural residence and between sex and rural residence
by fitting an interaction term in the multivariable models.
We used a likelihood ratio test to compare the model with
and without interaction and presented stratum-specific
estimates.
All analyses were performed using Stata 14 (Stata Corp,
College Station, TX, USA). This study was approved by
the Institutional Review Board of Aminu Kano Teaching
Hospital, Nigeria.
Results
We analysed data on 1381 TB cases enrolled between
January 2010 and December 2014. More than two-thirds
of the participants were between 15 and 44 years at the
time of treatment commencement. More than half (56.8%)
were males. Pulmonary disease was the most common
form of TB in participants (65.7%). Common extra-
pulmonary sites comprised the abdomen, spine, and the
CNS. Other less common sites included the skin, larynx
and adrenals. At the time of treatment commencement,
392 (28.4%) patients were rural residents and 550
(39.8%) were co-infected with HIV, of which only 90
(16.4%) were on anti-retroviral treatment (ART). The
distribution of age, HIV status, sex, and TB site of the
43 excluded patients were similar to those included in
this analysis. However, the patients excluded were more
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likely to be rural residents (41.9%), and less likely to
have a history of prior TB (4.7%).
Nearly half of the patients (46.1%) had a poor treat-
ment outcome after a total follow-up time of 6377.2
person-months (pm), giving a rate of 9.9/100 pm (95%
CI: 9.2–10.8). Of the 636 patients with poor outcome,
57.5% were lost to follow-up, 37.3% died during treatment,
and 5.2% failed treatment.
Crude analysis showed that nearly two-thirds (65.3%)
of the rural residents had a poor treatment outcome of
treatment, compared to 38.4% of urban residents. When
poor outcome was further broken down to specific
treatment outcome, among urban residents, 16.7% were
lost to follow-up, 3.0% failed treatment and 8.9% died
during treatment. While among rural residents, 13.1%
were lost to follow-up, 2.0% failed treatment and 46.0%
died. The distribution of explanatory variables across
treatment outcomes is shown in Table 1.
Univariable associations between residence and other
potential confounders (Table 2) showed that the majority
(81.4%) of rural residents had a clinical diagnosis, com-
pared to 60.8% of urban residents. Nearly half (42.9%) of
Table 1 Crude association between poor treatment outcome
and potential confounders, TB clinic, Aminu Kano Teaching
Hospital, Kano, Nigeria
Variable Total (%) Poor outcome P value (χ2)
Yes (%) No (%)
Age group (years)
15–24 252 91 (36.9) 159 (63.1)
25–34 382 169 (44.2) 213 (55.8)
35–44 323 139 (43.0) 184 (57.0)
45–54 181 105 (58.0) 76 (42.0)
55–64 82 45 (54.9) 37 (45.1)
> 65 70 44 (62.9) 26 (37.1) <0.001
Sex
Female 785 259 (43.5) 337 (56.5)
Male 596 377 (48.0) 408 (52.0) 0.005
Residence
Urban 989 380 (38.4) 609 (61.6)
Rural 392 256 (65.3) 136 (34.7) <0.001
Referral facility
DOTS-linked facility 611 245 (40.1) 366 (59.9)
Non DOTS-linked facility 710 371 (52.3) 339 (47.7) <0.001
TB confirmation
Bacteriological 461 126 (27.3) 335 (72.7)
Clinical 920 510 (55.4) 410 (44.6) <0.001
TB site
Pulmonary 912 370 (40.6) 542 (59.4)
Extra-pulmonary 220 95 (43.2) 125 (56.8)
Both 213 140 (65.7) 73 (34.3) <0.001
HIV/ART status
HIV- 662 292 (44.1) 370 (55.9)
HIV+ 550 264 (48.0) 286 (52.0)
Unknown HIV status 169 80 (47.3) 89 (52.7) 0.008
Previous TB treatment
No 1041 411 (39.5) 630 (33.8)
Yes 340 225 (66.2) 115 (33.8) <0.001
Table 2 Association between participant’s residence and
covariates, TB clinic, Aminu Kano Teaching Hospital, Kano,
Nigeria
Variable Urban (%) Rural (%) P value (χ2)
Age group (years)
15–24 196 (20.9) 56 (15.9)
25–34 291 (31.1) 91 (25.8)
35–44 237 (25.3) 86 (24.4)
45–54 114 (12.2) 67 (19.0)
55–64 56 (6.0) 26 (7.4)
> 65 43 (4.6) 27 (7.7) 0.002
Sex
Male 530 (53.6) 255 (65.1)
Female 459 (46.4) 137 (34.9) <0.001
Referral facility
DOTS-linked facility 484 (48.6) 127 (33.5)
Non DOTS-linked facility 458 (51.4) 252 (66.5) <0.001
TB confirmation
Bacteriological 388 (39.2) 73 (18.6)
Clinical 601 (60.8) 319 (81.4) <0.001
TB site
Pulmonary 707 (73.4) 205 (53.7)
Extra-pulmonary 155 (16.1) 65 (17.0)
Both 101 (10.5) 112 (29.3) <0.001
HIV status
HIV- 475 (48.0) 187 (47.7)
HIV+ 383 (38.7) 167 (42.6)
Unknown HIV status 131 (13.3) 38 (9.7) 0.02
Previous TB treatment
No 817 (82.6) 224 (57.1)
Yes 172 (17.4) 168 (42.9) <0.001
Treatment outcome
Cured 281 (32.9) 47 (13.4)
Treatment completed 328 (38.4) 89 (25.4)
Lost to follow-up 143 (16.7) 46 (13.1)
Died 76 (8.9) 161 (46.0)
Treatment failed 26 (3.0) 7 (2.0) <0.001
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rural residents had a history of previous TB treatment
compared to 17.4% of urban residents. The distribution
of rural residence was similar (p = 0.14) among patients
who were HIV-negative (28.3%), HIV-positive (30.4%) or
had unknown HIV status (22.5%). (Table 3).
The rate of poor outcome was higher among rural
residents (21.1/100 pm;95% CI:18.7–23.8) than in
urban residents (7.4/100 pm;95% CI: 6.6–8.1). The rate
of poor outcome was also higher among HIV-positive
patients (11.4/100 pm;95% CI: 10.1–12.8) compared to
HIV-negative patients (9.0/100 pm;95% CI: 8.0–10.1).
(Table 4).
In multivariable analysis, after adjusting for age, sex,
calendar year, mode of diagnosis, TB site, HIV status,
prior TB history, and referral source, rural residents
had 2.74 times (95% CI:2.27–3.29) the risk of a poor
treatment outcome compared to urban residents; while
HIV-positive patients had 1.4 times (95% CI:1.16–1.69)
the risk compared to HIV negative patients (Table 4).
Using the relative risks from the fully-adjusted model,
the estimated PAFs were 25.6 and 11.9% for rural residence
and HIV infection respectively.
We examined the joint effects of HIV infection and
sex with place of residence. Within each strata of HIV
Table 3 Association between participant’s HIV status on enrolment and covariates, TB clinic, Aminu Kano Teaching Hospital, Kano,
Nigeria
Variable HIV-negative (%) HIV-positive (%) HIV status unknown (%) P value (χ2)
Age group (years)
15–24 166 (26.8) 58 (11.3) 28 (18.1)
25–34 181 (29.2) 156 (30.3) 25 (29.0)
35–44 112 (18.1) 181 (35.2) 30 (19.4)
45–54 67 (10.8) 86 (16.7) 28 (18.1)
55–64 46 (7.4) 23 (4.5) 13 (8.4)
> 65 48 (7.7) 11 (2.1) 11 (7.1) <0.001
Sex
Male 395 (59.7) 296 (53.8) 94 (55.6)
Female 267 (40.3) 254 (46.2) 75 (44.4) 0.12
Referral facility
DOTS-linked facility 423 (63.9) 212 (42.8) 75 (45.7)
Non DOTS-linked facility 239 (36.1) 283 (57.2) 89 (54.3) <0.001
TB confirmation
Bacteriological 239 (36.1) 172 (31.3) 50 (29.6)
Clinical 423 (63.9) 378 (68.7) 119 (70.4) 0.11
TB site
Pulmonary 406 (62.5) 386 (72.3) 120 (74.5)
Extra-pulmonary 120 (18.5) 71 (13.3) 29 (18.0)
Both 124 (19.1) 77 (14.4) 12 (7.5) <0.001
Residence
Urban 475 (71.8) 383 (69.6) 131 (77.5)
Rural 187 (28.3) 167 (30.4) 38 (22.5) 0.14
Previous TB treatment
No 503 (76.0) 395 (71.8) 143 (84.6)
Yes 159 (24.0) 155 (28.2) 26 (15.4) 0.003
Treatment outcome
Cured 178 (30.7) 116 (23.9) 34 (24.3)
Treatment completed 192 (33.2) 170 (35.1) 5 (39.3)
Lost to follow-up 81 (14.0) 75 (15.5) 33 (23.6)
Died 111 (19.2) 111 (22.9) 15 (10.7)
Treatment failed 17 (2.9) 13 (2.7) 3 (2.1) 0.006
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status and sex, rates of poor outcome were higher in
rural residents. However, rates were highest among HIV-
negative rural residents and rural women respectively.
(Figs. 1 and 2) We found strong evidence of interaction
between rural residence and HIV status (p < 0.001), and
between rural residence and sex. Across strata of HIV
status, effect of rural residence was higher among HIV-
negative patients and women. (Table 5) Adjusted stratum-
specific RRs showed that among HIV negative patients,
rural residents had more than 4 times (RR:4.07;95%
CI:3.15–5.25) the risk of poor treatment outcome, while
among HIV-positive patients, rural residents had about
twice the risk (RR:1.99;95% CI:1.49–2.64).
Discussion
In this study, we found high levels of poor treatment
outcome among a cohort of patients attending a TB clinic
in urban Kano, Nigeria. We show that rural residents have
more than twice the risk of having a poor treatment
outcome when compared to urban residents, and this
relationship is modified by HIV status and sex. HIV-
positive patients also have a higher risk of poor treatment
outcome compared to HIV-negative patients. Our findings
show that rural residents who are HIV-negative are
substantially more at risk of poor treatment outcomes
than their HIV-positive counterparts. Rural women also
have a higher risk of poor treatment outcomes compared
to rural men.
We found rural residence to be an independent risk fac-
tor for poor TB treatment outcome. Though TB prevalence
has been shown to be higher in urban settings, [23] several
factors could explain poor treatment outcome among rural
residents, including: low individual and household income,
lower level of education, limited access to health-care, and
Table 4 Univariable and Multivariable analyses of effect of rural residence and poor treatment outcome using Poisson regression
showing crude and adjusted relative risks (RR) with 95% CIs, TB clinic, Aminu Kano Teaching Hospital, Kano, Nigeria
No with poor
outcome
Person-months
of follow-up
Rate
(95% CI)
Crude RR
(95% CI)
Minimally-adjusted
RR (95% CI)a
Fully adjusted
RR (95% CI)b
Residence
Urban 380 5163.4 7.4 (6.6–8.1) 1 1 1
Rural 256 1213.8 21.1 (18.7–23.8) 3.21 (2.71–3.81) 3.43 (2.89–4.07) 2.74 (2.27–3.29)
HIV status
HIV-negative 292 3252.2 9.0 (8.0–10.1) 1 1 1
HIV-positive 264 2319.3 11.4 (10.1–12.8) 1.27 (1.07–1.50) 1.71 (1.43–2.06) 1.40 (1.16–1.69)
HIV status unknown 80 805.7 9.9 (8.0–12.4) 1.11 (0.86–1.42) 0.98 (0.75–1.29) 0.85 (0.64–1.12)
aadjusted for age, sex and calendar year
badjusted for age sex, calendar year, referral facility, TB confirmation mode, TB site, HIV status, and previous TB treatment status
Fig. 1 Rates of poor treatment outcome according to HIV status and residence
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comorbid illnesses. In addition to poor coverage of TB
services in rural areas, rural residents may have to incur
extra out-of-pocket cost travelling to urban areas to access
care. Though drugs and microscopy services are provided
free by the National TB programme, hidden costs such
as lack of transportation, bad/inaccessible roads, and
need for supportive investigations may contribute to
poor treatment-seeking behaviour, or cause missed
clinic visits. [3, 24] In poor households, especially in
rural areas, choices have to be made on how to spend
scarce household resources, especially in the presence
of competing priorities. [25] Health seeking may there-
fore be delayed for household members and treatment
adherence may be compromised. Lost productivity on
days patients have to travel to the city to access care
may additionally affect household income. Attitudes
including fear of stigma can affect health seeking
behaviours and adherence to treatment. [26, 27] Women
also have poorer socio-economic status, treatment-seeking
behaviours, and healthcare access, and hence higher risk
of poor treatment outcomes. [3] Large patient turnout and
long waiting periods in large hospitals such as the study
Table 5 Effect of rural residence on poor treatment outcome stratified by HIV-status and sex showing stratum-specific relative risks
(RR) with 95%CIs, TB clinic, Aminu Kano Teaching Hospital, Kano, Nigeria
Variable Residence No with poor outcome/
person-months
Stratum-specific crude RR for poor
treatment outcome (95% CI)
Stratum-specific adjusted RR for
poor treatment outcome (95% CI)a
P-value for
interaction (LRT)b
HIV status
Negative Urban 159/2725.2 1 1
Rural 133/526.9 4.32 (3.44–5.45) 4.07 (3.15–5.25)
Positive Urban 163/1780.1 1 1
Rural 101/539.3 2.05 (1.60–2.62) 1.99 (1.49–2.64)
Unknown Urban 58/658.1 1 1
Rural 22/147.6 1.69 (1.04–2.76) 1.55 (0.88–2.73) <0.001
Sex
Male Urban 218/2678.7 1 1
Rural 159/829.1 2.36 (1.92–2.89) 2.16 (1.71–2.72)
Female Urban 162/2484.7 1 1
Rural 97/384.7 3.87 (3.01–4.97) 4.08 (3.06–5.44) 0.001
aadjusted for age, sex, calendar year, referral facility, TB confirmation mode, TB site, HIV status, and previous TB treatment status
bLikelihood ratio test
Fig. 2 Rates of poor outcome according to sex and residence
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site may deter patients from seeking care, and has been
shown to be associated with treatment default. [28] Such a
situation may lead to patients seeking care from unskilled
sources and further delay diagnosis and treatment. A TB
prevalence survey in Nigeria showed that among suspected
TB cases, rural residents were more likely to consult
traditional healers while urban residents were more likely
to consult pharmacy shops, commonly termed ‘chemists’.
[23] The use of traditional herbal medications is a
recognised risk factor for kidney and liver disease, [29, 30]
Traditional herbal medications may also interfere with
anti-TB drug metabolism with potential for reducing
efficacy. [31] Moreover, traditional healers are more
accessible to patients, particularly those residing in rural
areas. This preference for non-orthodox health care and
relatively easier access to traditional health providers may
increase the likelihood of unfavourable treatment outcomes.
[28] High levels of poor treatment outcome observed in this
cohort could be attributed to the high prevalence of
TB/HIV co-infection, poor treatment adherence, delays
in diagnosis and treatment, and misdiagnosis. HIV
infected persons are more likely to acquire active TB
infection and progress to active disease, and those co-
infected with TB are more likely to have poor treatment
outcomes, [32–34] though ART use may attenuate this
risk. [35, 36] Co-infection is associated with disease
progression. Adverse drug interactions, coinciding
toxicities, and high pill burden in co-infected patients
may affect adherence or result in treatment failure. [37]
Associated co-morbidities that may increase the risk of
poor outcomes are also more frequent among co-infected
patients. [3, 36, 38]
When we stratified our data by HIV status, the effect
of rural residence among HIV-negative persons was more
than twice that among HIV-positive persons. We antici-
pated their combined effects to be greater than a multi-
plicative relationship, such that patients who are both rural
residents and HIV-positive would have higher risks of poor
outcome, since both HIV infection and rural residence are
independent risk factors for poor treatment outcome.
Surprisingly, HIV-negative rural residents had highest risk
of poor treatment outcome. A possible explanation of our
findings of negative interaction between rural residence
and HIV infection is the relative success of decentralisation
of HIV care, including TB-HIV services. [39, 40] This
situation may have led to quicker diagnosis and treatment
among rural residents who are HIV-positive compared to
those who are HIV-negative, attenuating the effect of rural
residence among HIV-positive persons. [41] While HIV
services are provided by higher-cadre staff, the majority of
TB services especially in rural areas are provided by lower-
cadre health workers, with limited capacity to diagnose
smear-negative and extra-pulmonary TB. This may cause
delays in TB diagnosis and treatment that contribute to
unfavourable outcomes. Additionally, HIV-negative
patients from outside the city may face difficulties in
navigating through bureaucracies of referral in a large
teaching hospital. Stratifying our data by sex, we also
show that effect of rural residence on poor treatment
outcomes was higher among women than men. This
finding could be related to underlying biological and
social vulnerability, including co-morbidities such as
anaemia and undernutrition, pregnancy, geographic and
socio-cultural barriers to accessing care, and economic
dependency. [42–44]
Our findings indicate that rural residents are more
likely to have a poor treatment outcome, however, previ-
ous investigators have shown varying associations between
residence and treatment outcomes. In a UK study,
patients living in rural areas were less likely to complete
TB treatment compared to urban residents on crude
analysis, though the association was confounded by
factors such as age, sex, ethnicity, recent immigration to
UK and disease site. [21] Crude assessment of TB
treatment outcomes in the Solomon Islands from 2000 to
2011 showed almost similar proportions of treatment
success among urban and rural areas. [45] Adjusting
for age, sex, TB site and year of treatment, a 10-year
retrospective analysis of treatment outcomes in Ethiopia
showed that patients from rural areas were more likely to
have treatment success than those from urban areas. [46]
In Zimbabwe, after adjusting for age, sex and HIV-status,
urban residents were more likely to have an unfavourable
treatment outcome. [22] Hospital-based studies tend to
show that rural residence was associated with poor
treatment outcomes. [47–49] However, an analysis of
treatment outcomes from two treatment centres (urban
public and rural private) in southern Nigeria, revealed that
poor treatment outcome was associated with receiving
care at an urban public health facility. The majority of the
patients in the study (88%) received care from the private
health care facility (rural) and may not necessarily be
residing in rural areas. [50] It is possible that our data may
be missing milder cases from rural areas and we may have
overestimated poor treatment outcome because milder
cases are more likely to have better treatment outcomes.
However, since our study site is a tertiary hospital which
provides specialist care, our data will capture more severe
cases irrespective of place of residence and any over-
estimation of poor treatment outcome will also apply to
urban residents.
Assuming a causal relationship and absence of residual
confounding, we found that about a quarter of poor
outcomes could be averted, if the increased risk associ-
ated with rural residence could be eliminated. Decen-
tralisation of TB care to improve access to rural
residents could substantially reduce poor treatment
outcomes.
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Our findings have important implications for TB control.
Poorer treatment outcomes such as treatment failure and
loss to follow-up among rural residents can increase the
risks of further transmission within the community; drug
resistant TB; and catastrophic economic costs and burden
from treatment of disease complications on already
impoverished households. More frequent poor out-
comes among the younger and probably more economic-
ally and physically productive patients could directly affect
household income sources and have wider impact on the
basic needs of food and healthcare of other vulnerable
household members, such as young children and women.
TB/HIV co-infection has been traditionally recognised as a
risk factor for poor TB outcomes. However, following
expansion of HIV services which include HIV-TB care,
HIV-infected persons may have better access to TB care,
including referral and management of other co-morbidities
which may improve treatment outcomes. Our results
suggest that for patients who have to travel to access TB
care in a large treatment centre, being HIV-negative may
actually be detrimental to treatment outcomes. We believe
our findings are generalizable to many tertiary-level
facilities that provide TB care across the country, and
therefore the implications could have a much wider impact
on TB control in Nigeria.
Our results may be explained by individual socio-
cultural factors that may influence health and health care-
seeking among rural residents, however, we believe the
contextual effects of rural residence captures effects of
both compositional individual-level and group-level
factors. [15, 51] Due to the retrospective nature of this
study, we were limited by information available from
the TB registers, and as such we could not account for
other measures of disease severity including HIV stage
and other comorbid conditions. We may therefore have
over-estimated the effect of rural residence on treatment
outcome, if rural residents had more severe disease.
However, reasons for seeking care at an urban facility may
also be related to unavailability of TB care in rural areas
and not only referral for more severe disease. We also did
not account for anti-retroviral use among HIV-positive
patients, because only ART status at treatment initiation
was recorded and was not updated in the patient records
if ART was commenced during TB treatment. Thus, we
may have over-estimated the effect of HIV infection. It is
possible that the patients excluded could have a different
risk of poor treatment outcome because they were more
likely to be rural residents. However, other characteristics
of the excluded patients (age, sex, TB site, HIV status)
were similar to those included in this analysis. There may
be differences in causes and risk factors for death, loss
to follow-up or treatment failure that we may not have
captured in our analysis, as we grouped the different
sub-categories comprising poor treatment outcome as
one. Risk factors for treatment failure reported from
previous studies include drug resistance, severity of
disease, co-morbidities, positive culture at 2 months
[52, 53]; while low socio-economic status, poor adher-
ence, poor access to health care, substance abuse, fear
of stigma, lack of social support, and anti-TB side
effects have been implicated in treatment default. [27, 28]
However, risk factors for different poor treatment out-
comes have also been shown to overlap. [34]
Conclusion
Our findings show high rates of poor treatment outcome
in this large TB treatment centre. The effect of rural
residence on poor TB treatment outcome has implica-
tions on current and future interventions. There is a
need to more closely monitor rural-dwelling patients
accessing care in urban centres and to further decentralise
TB care to rural areas including strengthening of
community-based TB services in rural areas to improve
access to early diagnosis and treatment. Given that HIV
services have wider coverage and are better resourced
than TB services, facilities providing HIV care in rural
communities can expand TB services (diagnosis and
treatment) to residents irrespective of their HIV status.
This expansion would reduce delays in diagnosis and
treatment initiation, and the socio-economic risks and
treatment outcome consequences associated with trav-
elling to access care. Ultimately, resource-constrained
countries with high burden of TB and HIV as well as
other diseases should aim at integrating healthcare and
minimise emphasis on vertical programmes. Though
tailoring appropriate interventions toward persons at
risk of poor treatment outcome may have greater impact on
TB control than blanket population-wide interventions,
proposed interventions should in addition to individual-level
approaches also consider population-based sociocultural
and economic contexts. For instance, women empower-
ment, and girl-child education may be important in
northern Nigeria in improving the health status and
treatment-seeking behaviour of women and their families.
Social protection initiatives which include cash transfers,
microfinance credit schemes to improve income-producing
activities such as farming, and skills development and
capacity building will reduce household poverty and
mitigate the impact of unexpected and catastrophic
costs of illness on the household. Although TB care
coverage is less than satisfactory in many high TB-
burden countries, it is important that patients with TB
that reach the health system get a favourable treatment
outcome.
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